Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.
Ryota ShibakiYuichi OzawaSusumu NoguchiYusuke MurakamiEri TakaseYuichiro AzumaMasaru MaebeyaTakeya SugimotoAtsushi HayataTakahiro HayakawaShinya TamakiMasanori NakanishiShunsuke TeraokaHiroaki AkamatsuPublished in: Cancer medicine (2022)
Pre-ILS increased the risk of lung injury in patients of non-small cell lung cancer treated with osimertinib, while the severity of lung injury was not clearly affected by the presence of pre-ILS.